- Home
- BRT vs MRVI Comparison
BRT vs MRVI Comparison
Compare BRT & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- MRVI
- Stock Information
- Founded
- BRT 1972
- MRVI 2014
- Country
- BRT United States
- MRVI United States
- Employees
- BRT N/A
- MRVI N/A
- Industry
- BRT Real Estate Investment Trusts
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- MRVI Health Care
- Exchange
- BRT Nasdaq
- MRVI Nasdaq
- Market Cap
- BRT 291.9M
- MRVI 312.4M
- IPO Year
- BRT N/A
- MRVI 2020
- Fundamental
- Price
- BRT $16.09
- MRVI $2.23
- Analyst Decision
- BRT Strong Buy
- MRVI Hold
- Analyst Count
- BRT 1
- MRVI 10
- Target Price
- BRT $21.00
- MRVI $6.84
- AVG Volume (30 Days)
- BRT 28.6K
- MRVI 1.8M
- Earning Date
- BRT 05-08-2025
- MRVI 05-12-2025
- Dividend Yield
- BRT 6.27%
- MRVI N/A
- EPS Growth
- BRT N/A
- MRVI N/A
- EPS
- BRT N/A
- MRVI N/A
- Revenue
- BRT $98,162,000.00
- MRVI $241,856,000.00
- Revenue This Year
- BRT $0.73
- MRVI N/A
- Revenue Next Year
- BRT $5.64
- MRVI $10.73
- P/E Ratio
- BRT N/A
- MRVI N/A
- Revenue Growth
- BRT 2.71
- MRVI N/A
- 52 Week Low
- BRT $14.61
- MRVI $1.67
- 52 Week High
- BRT $20.22
- MRVI $10.03
- Technical
- Relative Strength Index (RSI)
- BRT 55.97
- MRVI 54.40
- Support Level
- BRT $15.50
- MRVI $2.10
- Resistance Level
- BRT $16.01
- MRVI $2.41
- Average True Range (ATR)
- BRT 0.44
- MRVI 0.14
- MACD
- BRT 0.10
- MRVI 0.01
- Stochastic Oscillator
- BRT 94.65
- MRVI 70.97
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.